TB: uniting scientists to tackle one of the world’s biggest killers

Following the science of oxygen to discover solutions for anaemia

Following the science of oxygen to discover solutions for anaemia

Using vaccine science to combat antimicrobial resistance

Alongside antibiotics, vaccines are an important and yet broadly underused tool in reducing the spread of antibiotic resistance globally.

Looking deeper into lupus

Professor Roger Abramino Levy is a former Adjunct Professor of Rheumatology who since 2018 has been a Global Medical Expert at GSK.

Immuno-Oncology: Integrating innovation into standard of care practice

In today’s remarkable field of Immuno-Oncology, there is still much yet to discover.

Asthma management: it’s time to get personal

Could ‘treatable traits’ help scientists uncover a more personalised approach to asthma patient care?

TB: uniting scientists to tackle one of the world’s biggest killers

Tuberculosis (TB) is one of the top ten causes of deaths worldwide.

Making the switch: how we’re improving access to proven medicines

Switching a medicine from prescription OTC places the power of managing everyday health conditions with the patient.

The lung microbiome and the future management of respiratory disease

Your lungs are full of micro-organisms. Some are welcome guests and some are uninvited gate-crashers

Revealing the beautiful complexity of the immune system

David Roth works in immunology research and development. Here he talks to us about the complexity of the body’s defence system and how we’re working to unlock its hidden secrets to help bring new medicines to patients.

GSK’s SAM technology could revolutionise vaccines

Jeff Ulmer explains how synthetic Self-Amplifying mRNA (SAM) and ground-breaking partnerships may help us fight more conditions faster and more efficiently than ever before.

Our focus on developing the next generation of antibiotics

Developing new antibiotics is very difficult, both scientifically and financially. But our antibacterial research is focused on developing the next generation of antibiotics and we have an active pipeline of potential new medicines in development.

Delivering potentially transformational medicines through R&D innovation in Oncology

Axel Hoos, SVP, Oncology R&D, explains how GSK is driving innovation in Oncology R&D

How do you test medicines in the real world?

For decades, randomised clinical trials have been a cornerstone of pharmaceutical science, reassuring patients that their medicines have been thoroughly tested. But there’s a wide world beyond the research clinic doors and the data collected in these highly controlled environments are just the first chapter of a rich story.

The vaccines of tomorrow

Join our leading scientists as they go behind the science of vaccine technology.

Inclusive design: making our differences invisible

Great design is almost invisible, it’s something that is seamless and frictionless. But for anyone who has experienced poor design, the frustration and hardship are all too evident.

Unravelling the mysteries of the human genome with functional genomics

What is functional genomics technology and how can we use it to improve our chances of finding the right targets for potential medicines?

Why collaboration is essential to achieving new breakthroughs in vaccines

Emmanuel Hanon, Senior Vice President R&D at GSK Vaccines shares how one idea combined with the right type of collaboration could change the future of vaccine development.

Tackling tomorrow’s health challenges today

Our Chief Scientist, Rino Rappuoli, explains how science is helping create the vaccines of tomorrow

From eucalyptus toothpaste to a brew for the flu: tailoring products to different tastes

Find out where these ideas for different tastes come from and how they make it onto the shelf.

STEM – inspiring tomorrow’s science and engineering superstars

Meet this year’s GSK UK Young Scientist and Engineers of the Year.

We need more women in science to create the inclusive technologies of the future

Nidhi Aggarwal, Global Packaging Development Manager, Consumer Healthcare, tells how she reached her current role and explains why we need more diversity of thought in science and applied fields.

Using the immune system to fight cancer

A recent paper by GSK scientists revealed a potential new class of immunotherapy drugs to treat some cancers.

From bench to bedside: lessons in converting science into impact

Pauline Williams, Head of Global Health R&D, shares a unique perspective on what it takes to research new treatments and deliver them to patients around the world.

How a chance encounter led to a world-first toothpaste

Did you know that NovaMin, one of the key technologies in our toothpaste, is actually a bioactive glass most commonly used to repair bones?

Inside the Open Lab

How does the Tres Cantos Open Lab offer top international scientists and academics the opportunity to pursue their own projects as part of an integrated team?

You, me and 23andMe: discovering new medicines through genetics

Explore how our new collaboration with 23andMe could help unlock the medicines of tomorrow.

How do consumer insights fuel our innovation?

By asking our consumers what matters to them, we can keep innovating and evolving our products.

How genomics is driving a new era of drug discovery

We’re in a new era of drug discovery because of a fundamental change in our understanding of human biology.

How are we redefining research in HIV?

Shari Gordon works in the HIV Cure Center in North Carolina, a public-private company with one goal: discovering a cure for HIV/AIDS.

Lupus: the search for a cure continues

Doctors and their patients face an ongoing battle to manage this chronic and sometimes debilitating and life-threatening condition. See how we’re trying to help.

30 years and counting: the fight against HIV

How to find a treatment for a disease with no idea what that disease actually is.

The digitalisation lab: bringing the digital age to manufacturing

We are developing world-class manufacturing innovation to help us bring medicines and consumer healthcare products to people.

COPD: Our relentless pursuit for better breathing

Every person with COPD is different, with different needs, different challenges and different goals. See how we're innovating to determine the right treatment for the right patient.

Getting on target in autoimmune diseases

What happens when the cells in our immune system malfunction?

How smart is your inhaler?

As we investigate new treatments, the ‘internet of things,’ is allowing us to explore the benefits of interconnectivity and the rich patient data that these technologies can provide.

Scientists or detectives? Seeking new clues in COPD

It is now widely accepted that COPD is not a uniform disease, but effects of the disease can impact people differently.

Inhaler innovation: more than a simple piece of plastic

At first glance, an inhaler may look like a simple piece of plastic. But inside, a complicated process and an internal ‘engine’ operate seamlessly...

Vaccine manufacture: it’s complicated

Vaccine manufacture can take anywhere between 6 and 26 months. That’s not to mention the time required to research and develop a new vaccine, which can take up to 30 years.

Turbocharging the effect of vaccines

When extracted and purified, a compound from the soap bark tree can be mixed with other ingredients to create an ‘adjuvant’, turbocharging the body's immune defences.

Outgrowing asthma

Why is it that some people, particularly children, grow out of their asthma? That’s a question our scientists are asking as part of our research to better understand the disease.

Targeting the immune system through open innovation

A functioning immune system is crucial to our health - but what is its role beyond such things as keeping colds at bay and fighting infections?

Cell and gene therapy: a new era of medicine

If we can pinpoint a faulty gene and correct it, could we potentially find a way to cure genetic diseases?

Neuroscience: on the brain

The number of people living with dementia worldwide is set to treble by 2050 to 135 million, according to the World Health Organization.